Lilly Pays InnoCare $100 Million Upfront in Discovery Pact Worth Up to About $3.25 Billion in Milestones

What happened

Eli Lilly and Beijing-based InnoCare Pharma announced a research collaboration on Sept. 24 in which Lilly will pay $100 million upfront. According to BioSpace, InnoCare is eligible for up to about $3.25 billion in development and commercial milestone payments, plus single-digit tiered royalties on net sales of any products that reach the market.

The companies will use InnoCare’s drug discovery platform to develop candidates for up to five targets. The indications have not been disclosed.

Deal details

• Upfront: $100 million.
• Milestones: Up to about $3.25 billion in development and commercial milestones.
• Royalties: Single-digit tiered royalties on annual net sales.
• Scope: Up to five targets described as having critical unmet medical needs.

InnoCare focuses on cancer and autoimmune diseases. BioSpace noted the company’s history with partners on its oral BTK inhibitor orelabrutinib. Biogen paid $125 million upfront in 2021 to license the drug for multiple sclerosis, with up to $812.5 million in milestones, before terminating that agreement in February 2023 and returning the asset. In October 2025, Zenas BioSciences committed $100 million for orelabrutinib and other autoimmune candidates in a deal that could exceed $2 billion with milestones.

Lilly’s dealmaking

The InnoCare agreement adds to an unusually active year for Lilly. BioSpace listed several recent transactions:

• Up to $2.875 billion for Merida Biosciences in late August, for an early-stage candidate in thyroid eye disease and Graves’ disease.
• $2.8 billion upfront plus up to $1 billion in contingent value rights for AtaiBeckley in July, marking Lilly’s entry into psychedelics.
• A deal worth up to $7 billion for Kelonia Therapeutics in April.
• A deal worth up to $7.8 billion for Centessa Pharmaceuticals in March.

BioPharma Dive separately reported earlier in September that Lilly had made about a dozen acquisitions since the start of 2026, roughly four times the count of its closest rivals.

Why it matters for the sector

Lilly’s revenue from its obesity and diabetes medicines has given it financial capacity that few drugmakers can match, and it has used that capacity to buy and license across therapeutic areas. The InnoCare deal is a discovery-stage agreement rather than an acquisition, but it follows the same strategy of building a broad pipeline through external innovation.

The deal also fits the continuing wave of Western licensing from China. Large drugmakers have been drawn to the speed and cost efficiency of Chinese research organizations, and multi-target discovery agreements let them access that capacity without buying a company outright. The modest upfront payment relative to milestone potential is typical of early-stage collaborations, where most value depends on candidates reaching the clinic and beyond.

For InnoCare, the agreement provides upfront cash and a second large pharma relationship after its experience with Biogen. Platform deals can be valuable because they generate income without requiring the company to give up its lead clinical assets.

Multi-target agreements also spread risk for the buyer. If one target fails in validation, others may still produce candidates, and the milestone structure means Lilly pays substantially more only for programs that advance.

Single-digit royalties are consistent with an early discovery agreement, in which the licensee bears most of the development cost and risk. Royalty rates generally rise for assets licensed at later stages, when clinical data reduce uncertainty.

The undisclosed indications leave open whether the work will draw on InnoCare’s strengths in cancer and autoimmunity or extend into other areas where Lilly has been investing.

What to watch

• Disclosure of the therapeutic areas or targets selected under the collaboration.
• Additional Lilly business development as the company continues to expand its pipeline.
• Policy developments affecting licensing agreements between Western drugmakers and China-based biotechs.
• Progress of InnoCare’s own pipeline, including orelabrutinib.

Sources: BioSpace, BioPharma Dive

How a Multi-Target Discovery Collaboration Unfolds

Agreements covering “up to five targets” follow a lifecycle that can stretch over many years. A typical sequence looks like this:

1. Target nomination. The pharma partner proposes targets, often ones it has prioritized internally but lacks the chemistry to address.
2. Discovery work. The platform company designs and screens molecules, aiming to reach agreed criteria for potency, selectivity and drug-like properties.
3. Candidate nomination. When a molecule meets those criteria, it is nominated as a development candidate, which often triggers a milestone payment.
4. Handoff. The pharma partner typically takes over preclinical safety studies, clinical trials and regulatory work.
5. Clinical and commercial milestones. Further payments are tied to trial starts, approvals and sales thresholds, followed by royalties.

Not every target reaches a candidate, and not every candidate reaches the clinic. Headline values assume the best case across all programs.

Putting the Headline Number in Perspective

Dividing the potential milestones across five targets gives a rough sense of scale: about $650 million per target if every program succeeded at every stage. In practice, the realized value of discovery collaborations is usually far lower, because many programs stop during preclinical work or early trials. The $100 million upfront payment is the most concrete measure of how much Lilly is committing today.

Single-digit royalties on any eventual product sales reflect the early stage of the work. The partner that funds development and carries clinical risk generally keeps the larger share of commercial returns.

A Primer on BTK Inhibitors

InnoCare’s history with orelabrutinib comes up often in coverage, so a brief explanation helps. Bruton’s tyrosine kinase is an enzyme that plays a key role in signaling inside B cells, a type of immune cell. Blocking BTK can slow the growth of certain B-cell cancers and dampen immune activity in some autoimmune diseases. Several BTK inhibitors are approved for blood cancers, and developers have been testing the class in conditions such as multiple sclerosis and other immune-mediated diseases.

Questions Readers Ask

Why do Western drugmakers license from Chinese biotechs?

Speed and cost efficiency in discovery and early clinical work are frequently cited reasons. Licensing also lets the buyer access novel chemistry without acquiring a company outright.

What does it mean when a partner returns an asset?

Terminating a license and returning rights usually reflects a change in the partner’s strategy or its view of the program’s prospects. The originator can then pursue the asset itself or with a new partner, as InnoCare did.

Why keep the indications confidential?

Disclosing targets can tip off competitors. Companies commonly reveal details only once programs reach the clinic.

What should readers look for in future updates?

Candidate nominations, first-in-human trial starts and any milestone payments reported in either company’s financial statements are the clearest signs that a discovery collaboration is producing results.

This article is for general information only and is not investment advice.